lectin
structur
divers
group
protein
specif
revers
bind
carbohydr
act
recognit
adhes
molecul
signal
transduc
involv
plethora
physiolog
function
possess
least
one
carbohydr
bind
domain
domain
combin
enabl
multival
crosslink
glycoconjug
first
discov
extens
investig
lectin
plant
howev
recent
year
fungal
lectin
gain
attent
fungal
lectin
differ
counterpart
speci
uniqu
structur
bind
specif
shown
stabl
protein
resist
chang
ph
temperatur
well
proteolyt
digest
strengthen
potenti
applic
biotechnolog
medicin
previous
isol
character
biochem
novel
lectin
macrolepiota
procera
design
mpl
mpl
structur
similar
b
subunit
ricin
lectin
castor
bean
ricinu
communi
canon
member
lectin
fungal
type
lectin
exhibit
remark
divers
bind
partner
includ
carbohydr
protein
mpl
activ
dimer
possess
strong
carbohydr
bind
domain
specif
termin
nacetyllactosamin
put
carbohydr
bind
domain
unknown
specif
cell
membran
protein
lipid
specif
glycosyl
potenti
bind
site
lectin
could
therefor
appli
target
deliveri
drug
sinc
express
carbohydr
structur
alter
progress
cancer
lectin
distinguish
particular
cell
subset
enabl
precis
recognit
cancer
cell
ligand
use
activ
drug
deliveri
system
besid
recogn
specif
glycosyl
pattern
cancer
cell
lectin
trigger
intern
use
deliv
molecul
cell
sort
intracellular
compart
b
subunit
ricin
enabl
entri
cell
least
six
differ
rout
current
investig
protein
carrier
lysosom
deliveri
enzym
replac
therapi
lysosom
target
includ
peptidas
constitut
challeng
cancer
treatment
invas
cancer
cell
known
depend
degrad
extracellular
matrix
ecm
barrier
prevent
cancer
cell
migrat
invad
distant
site
ecm
degrad
extracellularli
predominantli
matrix
metallopeptidas
howev
process
greatli
acceler
fragment
ecm
protein
intern
cancer
cell
ultim
degrad
within
lysosom
other
shown
inhibit
lysosom
peptidas
impair
cancer
cell
invas
cathepsin
lysosom
cystein
peptidas
particularli
import
process
target
lysosom
small
inhibitor
enter
cell
diffus
specif
protein
inhibitor
clitocypin
cystatin
c
clitocypin
fungal
inhibitor
cystein
peptidas
share
fold
mpl
inhibitor
papainlik
cystein
peptidas
papain
cathepsin
l
v
k
weak
inhibitor
cathepsin
b
human
cystatin
c
potent
inhibitor
papainlik
cystein
peptidas
includ
cathepsin
b
howev
abil
protein
inhibitor
enter
cell
local
within
lysosom
low
deliveri
system
abl
guid
peptidas
inhibitor
lysosom
could
significantli
enhanc
cell
uptak
increas
inhibit
lysosom
proteolyt
activ
studi
appli
mpl
recombin
lectin
macrolepiota
procera
potenti
deliveri
peptidas
protein
inhibitor
lysosom
evalu
effect
mpl
differ
cancer
cell
line
bind
partner
cell
membran
mechan
intern
final
destin
within
cell
order
test
potenti
carrier
molecul
target
deliveri
construct
fusion
protein
mpl
peptidas
inhibitor
investig
cell
uptak
effect
cancer
cell
invas
given
mpl
report
toxic
toward
model
nematod
caenorhabd
elegan
test
effect
differ
human
cell
line
viabil
loss
assay
mpl
shown
nontox
suspens
cell
jurkat
nondifferenti
cell
adher
cell
hela
neot
phorbol
pma
differenti
cell
three
differ
concentr
three
differ
time
point
h
h
h
tabl
supplementari
tabl
bind
mpl
cell
surfac
receptor
depend
glycan
bind
shown
util
mpl
mutant
inhibit
assay
lactos
figur
supplementari
figur
mpl
bound
surfac
hela
neot
cell
almost
immedi
ad
cell
cultur
medium
minut
lectin
could
alreadi
observ
insid
cell
figur
supplementari
figur
mutant
inact
bind
site
function
bind
site
show
characterist
regard
cell
entri
similar
wildtyp
mpl
indic
bind
site
mediat
intern
inde
mutant
inact
bind
site
enter
cell
figur
supplementari
figur
similarli
lactos
competit
inhibitor
glycan
bind
mpl
ad
medium
intern
mpl
block
addit
lactos
howev
affect
bind
mutant
figur
supplementari
figur
initi
weak
bind
cell
surfac
first
minut
addit
observ
sampl
contain
lactos
figur
supplementari
figur
presum
result
nonspecif
bind
similar
bind
intern
mpl
observ
cell
line
test
pma
differenti
nondifferenti
jurkat
cell
supplementari
figur
shortli
intern
mpl
could
observ
endosom
dot
like
structur
compon
golgi
apparatu
ga
shown
hela
neot
cell
doublelabel
golgi
apparatu
marker
antimpl
antibodi
figur
supplementari
figur
mpl
intern
clathrindepend
endocytosi
shown
employ
endocytosi
inhibitor
inhibit
clathrinindepend
endocytosi
filipin
iii
inhibitor
caveola
format
effect
mpl
uptak
figur
supplementari
figur
howev
inhibit
clathrinmedi
endocytosi
chlopromazin
complet
abolish
uptak
mpl
cell
coloc
cell
membran
label
embed
palmitoyl
gfp
figur
supplementari
figur
similar
accumul
membran
bound
mpl
observ
presenc
lactos
figur
supplementari
figur
furthermor
mpl
coloc
transferrin
receptor
wellestablish
marker
clathrin
depend
pathway
supplementari
figur
final
high
rate
intern
mpl
support
clathrin
mediat
endocytosi
sinc
consid
process
around
fold
faster
clathrin
independ
especi
caveolaedepend
endocytosi
min
blockad
retrograd
transport
earli
endosom
golgi
apparatu
caus
decreas
accumul
mpl
golgi
apparatu
figur
supplementari
figur
stain
acid
subcellular
compart
lysotrack
red
upon
blockad
retrograd
transport
show
signific
coloc
fitc
label
mpl
incub
supplementari
figur
mpl
retain
endolysosom
compart
extend
period
time
h
hela
figur
neot
cell
supplementari
figur
three
glycosyl
membran
protein
two
secret
glycosyl
protein
identifi
target
mpl
neot
cell
tabl
order
determin
specif
mpl
target
neot
cell
membran
fraction
isol
incub
mpl
result
complex
coimmunoprecipit
comparison
coimmunoprecipit
form
absenc
presenc
lactos
reveal
three
major
band
correspond
target
protein
mpl
neot
cell
supplementari
figur
best
protein
coverag
obtain
mass
fingerprint
aminopeptidas
n
isoform
integrin
isoform
integrin
three
target
cell
membran
protein
known
glycosyl
site
potenti
bind
mpl
coimmunoprecipit
aminopeptidas
n
integrin
mpl
confirm
western
blot
analysi
supplementari
figur
less
well
cover
secret
glycosyl
protein
glycoprotein
fibronectin
mpl
aminopeptidas
n
coloc
neot
cell
figur
coloc
observ
min
addit
lectin
increas
time
reveal
signific
coloc
signal
mostli
intracellularli
begin
experi
small
portion
aminopeptidas
n
detect
intracellularli
indic
mpl
increas
intern
rate
mpl
coloc
integrin
subunit
neot
figur
hela
cell
shown
shortli
addit
cell
cultur
medium
antibodi
rais
subunit
use
analys
subcellular
distribut
integrin
integrin
subunit
assembl
integrin
subunit
form
heterodimer
receptor
two
integrin
isoform
identifi
coimmunoprecipit
mpl
within
minut
colocalis
occur
presum
cell
membran
wherea
min
protein
could
seen
intracellularli
min
extent
coloc
chang
remain
throughout
experi
h
part
integrin
howev
remain
cell
membran
order
explor
potenti
mpl
deliv
biolog
drug
intracellular
target
construct
two
recombin
fusion
protein
mpl
peptidas
inhibitor
clitocypin
cltmpl
cystatin
c
cyscmpl
clitocypin
clt
uniprot
id
cystatin
c
cysc
uniprot
id
low
molecular
weight
cystatin
c
kda
clitocypin
kda
therefor
suitabl
construct
fusion
furthermor
cystatin
c
order
magnitud
potent
cystein
cathepsin
inhibitor
compar
clitocypin
peptidas
inhibitor
ntermin
part
fusion
connect
lectin
domain
ctermin
part
fusion
long
flexibl
peptid
linker
gggg
form
ntermin
region
fusion
describ
ensur
retent
integrityact
subunit
fusion
protein
cltmpl
cyscmpl
express
e
coli
purifi
figur
lectin
peptidas
inhibitor
domain
fusion
activ
determin
haemagglutin
assay
measur
inhibitori
activ
cystein
peptidas
papain
cyscmpl
agglutin
human
blood
group
b
erythrocyt
wherea
cltmpl
even
figur
howev
immunocytochem
analysi
use
antimpl
specif
antibodi
show
cltmpl
enter
subcellular
compart
hela
shown
neot
cell
supplementari
figur
indic
lectin
domain
activ
cyscmpl
cltmpl
activ
papain
constant
inhibit
ki
rang
determin
unlink
cysc
clt
figur
fusion
cyscmpl
cltmpl
enter
neot
cell
supplementari
figur
hela
cell
shown
fashion
similar
unlink
mpl
shortli
addit
cyscmpl
supplementari
figur
cltmpl
supplementari
figur
enter
neot
cell
coloc
compon
ga
wherea
prolong
incub
present
endolysosom
system
mpl
fusion
retain
endolysosom
compart
extend
time
period
supplementari
figur
test
effect
cyscmpl
cltmpl
fusion
activ
intracellular
peptidas
cathepsin
b
l
supplementari
figur
activ
measur
whole
cell
lysat
prepar
cell
treat
either
fusion
protein
mpl
alon
combin
peptidas
inhibitor
one
two
hour
activ
cathepsin
l
inhibit
cell
treat
cyscmpl
fusion
inhibit
activ
compar
control
activ
cathepsin
b
reduc
cell
treat
cyscmpl
fusion
inhibit
combin
unlink
cysc
mpl
inhibit
combin
unlink
clt
mpl
inhibit
cell
lysat
treat
clt
cysc
alon
chang
activ
cathepsin
b
l
detect
reduc
intracellular
ecm
degrad
intern
peptidas
inhibitor
may
decreas
invas
tumor
cell
matrigel
analys
intracellular
degrad
ecm
follow
dqcollagen
iv
neot
cell
treat
fusion
protein
mpl
alon
combin
peptidas
inhibitor
flow
cytometr
analysi
show
signific
reduct
dqcollagen
iv
degrad
cell
treat
cyscmpl
fusion
similar
effect
intracellular
proteas
inhibitor
figur
wherea
cltmpl
fusion
effect
shown
next
step
examin
effect
mpl
fusion
invas
neot
cell
model
aggress
breast
cancer
cell
assay
invas
reli
effect
degrad
matrigel
coat
gelatin
protein
mixtur
resembl
ecm
fusion
reduc
invas
neot
cell
matrigel
figur
invas
graph
particular
cyscmpl
fusion
lower
invas
speed
significantli
slope
linear
regress
curv
cumul
number
invad
cell
area
curv
compar
control
figur
right
column
graph
supplementari
figur
effect
even
pronounc
effect
intracellular
proteas
inhibitor
supplementari
figur
use
unlink
cysc
mpl
alon
result
speed
invas
cumul
number
invad
cell
compar
control
wherea
combin
unlink
cysc
mpl
led
reduc
cumul
number
invad
cell
due
lower
invas
speed
begin
experi
figur
right
column
graph
supplementari
figur
cltmpl
fusion
also
lower
invas
speed
cumul
number
invad
cell
figur
right
column
graph
although
effect
pronounc
case
cyscmpl
combin
unlink
clt
mpl
chang
significantli
either
invas
speed
cumul
number
invad
cell
lectin
consid
molecul
capabl
target
deliveri
biolog
drug
intracellular
target
sinc
specif
bind
glycoconjug
target
cell
trigger
intern
studi
demonstr
fungal
lectin
mpl
edibl
mushroom
macrolepiota
procera
bind
strongli
aminopeptidas
integrin
receptor
glycoprotein
overexpress
sever
type
cancer
cell
recogn
candid
specif
cell
target
ligandreceptor
bind
mpl
trigger
cell
uptak
clathrindepend
endocytosi
result
accumul
ga
endolysosom
vesicl
figur
similar
bind
intern
behaviour
also
demonstr
mpl
fuse
protein
fusion
mpl
cystein
peptidas
inhibitor
significantli
improv
deliveri
endolysosom
vesicl
result
greatli
reduc
degrad
ecm
lysosom
target
cystein
cathepsin
consequ
decreas
migrat
invas
cancer
cell
mpl
differ
fungal
entomotox
nematotox
lectin
shown
neg
effect
prolifer
mammalian
cell
line
treatment
human
cell
line
show
even
fairli
high
concentr
mpl
effect
cell
viabilityprolifer
rapidli
intern
accumul
within
certain
subcellular
compart
intern
mpl
human
cell
depend
function
bind
site
nematotox
mpl
link
site
unknown
carbohydr
bind
specif
similar
nematotox
type
lectin
cnl
exhibit
antiprolif
effect
human
cell
line
specif
leukem
cell
depend
carbohydr
bind
furthermor
bind
actinoporintyp
lectin
xcl
abl
former
also
highli
toxic
insect
show
antiprolif
effect
variou
mammalian
cell
line
mpl
rapidli
intern
variou
human
cell
line
shortli
intern
major
mpl
coloc
strongli
signal
label
compon
ga
figur
rout
earli
endosom
toward
compon
ga
ie
transgolgi
network
tgn
continu
endoplasm
reticulum
er
shown
plant
toxin
ricin
bacteri
shiga
toxin
inhibit
retrograd
transport
reveal
exist
anoth
appar
slower
target
pathway
sort
mpl
lysosom
vesicl
furthermor
colocalis
mpl
endolysosom
marker
lysotrack
follow
prolong
incub
hela
neot
cell
show
intern
mpl
retain
within
acid
subcellular
compart
least
h
hour
similarli
lectin
xcl
abl
locat
respect
intracellular
local
site
h
h
respect
small
differ
carbohydr
bind
specif
appar
influenc
intracellular
rout
final
destin
lectin
cell
mpl
specif
termin
nacetyllactosamin
local
ga
endolysosom
system
similarli
mammalian
bind
long
polynacetyllactosamin
chain
local
golgi
system
disappear
without
accumul
lysosom
lectin
xcl
bind
specif
glycan
local
late
endosom
lysosom
ga
hand
lectin
abl
appar
glycanbindingspecif
xcl
show
perinuclear
accumul
membran
bound
vesicl
furthermor
fungal
chimerolectin
moa
specif
structur
accumul
late
endosom
local
either
earli
endosom
ga
er
despit
differ
intracellular
sort
fungal
lectin
mpl
xcl
abl
moa
still
exploit
clathrindepend
endocytosi
latter
two
howev
also
util
clathrinindepend
pathway
mpl
intern
via
clathrinmedi
endocytosi
bind
target
cell
membran
probabl
influenc
intracellular
sort
final
destin
clathrinco
pit
form
spontan
absenc
ligand
stabil
endocytosi
ligandreceptor
depend
process
therefor
hypothes
mpl
endocytos
via
ligand
induc
intern
glycosyl
receptor
mpl
could
mimic
ligand
induc
receptor
dimer
lead
intern
ligandreceptor
clathrinco
vesicl
could
bind
lipid
raft
associ
glycolipid
intern
clathrindepend
pathway
latter
mechan
entri
alreadi
shown
shiga
cholera
toxin
glycolipid
exclud
bind
target
mpl
shown
use
lectin
blot
thin
layer
chromatographi
describ
coimmunoprecipit
mass
spectrometri
reveal
sever
potenti
mpl
bind
glycoprotein
neot
cell
model
cell
line
aggress
breast
cancer
strongest
target
appear
aminopeptidas
n
kda
glycosyl
protein
carri
n
olink
glycan
aminopeptidas
n
metallopeptidas
involv
proteolyt
process
variou
extracellular
protein
howev
independ
enzymat
activ
aminopeptidas
n
implic
regul
process
angiogenesi
antigen
present
celltocel
adhes
infect
corona
virus
colocalis
aminopeptidas
n
mpl
neot
cell
weak
shorter
time
point
min
howev
prolong
incub
h
coloc
signal
increas
within
endolysosom
dotlik
structur
suggest
increas
intern
aminopeptidas
n
aminopeptidas
n
normal
endocytos
constitutivephysiolog
sort
mechan
polar
epitheli
cell
human
liver
cancer
cell
found
target
distinct
sort
endosom
eventu
endolysosom
clathrin
dynamindepend
manner
dynam
process
accord
slow
endolysosom
target
mpl
furthermor
shown
intern
aminopeptidas
n
trigger
bind
ab
coronaviru
drug
vesicl
contrast
human
galectin
specif
bind
polynacetyllactosamin
repeat
unit
anoth
strong
aminopeptidas
n
ligand
fail
induc
intern
apart
aminopeptidas
n
mpl
also
bound
integrin
receptor
figur
protein
overexpress
breast
cancer
cell
integrin
famili
heterodimer
cell
surfac
receptor
mediat
adhes
cell
protein
ecm
bind
mpl
integrin
receptor
caus
partial
intern
rapid
transloc
toward
galik
structur
integrin
dynam
structur
constantli
endocytos
plasma
membran
format
clathrinco
pit
caveolin
vesicl
lipid
raft
earli
endosom
integrin
recycl
back
plasma
membran
endosom
perinuclear
recycl
endosom
recycl
directli
earli
endosom
howev
recent
shown
hela
cell
endocytos
integrin
traffic
recycl
endosom
tgn
compon
tgn
play
ratelimit
role
integrin
traffick
intern
integrin
also
induc
specif
ab
well
bind
galectin
therefor
hypothes
bind
integrin
recycl
tgn
could
explain
fast
intern
target
mpl
compon
ga
fast
intern
observ
also
lectin
moa
induc
intern
degrad
integrin
howev
clear
whether
moa
bind
integrin
directli
final
two
secret
protein
detect
mpl
target
fibronectin
glycoprotein
former
extracellular
matrix
compon
latter
signal
molecul
even
though
appear
irrelev
process
mpl
intern
hypothes
mpl
could
crosslink
compon
receptor
cell
surfac
potenti
lead
intern
furthermor
cell
line
show
reduc
adhes
fibronectin
treat
mpl
determin
realtim
cell
analysi
shown
nevertheless
possibl
two
protein
contamin
membran
purif
protocol
could
exclud
abil
mpl
bind
tumorassoci
protein
induc
uptak
cell
explor
deliv
biolog
drug
intracellular
target
hypothesi
test
cystein
cathepsin
lysosom
peptidas
involv
tumor
migrat
invas
metastasi
cystein
cathepsin
promin
one
cancer
cathepsin
b
involv
degrad
ecm
protein
type
iv
collagen
laminin
fibronectin
thu
facilit
growth
invas
tumor
cell
surround
tissu
vasculatur
partial
extracellular
degrad
ecm
fragment
intern
tumor
cell
complet
degrad
lysosom
cathepsin
b
peptidas
demonstr
low
molecular
weight
inhibitor
cathepsin
b
abl
inactiv
intra
extracellular
fraction
cathepsin
b
effect
impair
tumor
progress
hold
endogen
protein
inhibitor
cystatin
howev
uptak
cell
transport
lysosom
limit
effect
inhibit
enhanc
deliveri
cystatin
lysosom
therefor
creat
fusion
protein
mpl
cystatin
c
cysc
clitocypin
clt
fusion
follow
intern
rout
unlink
mpl
supplementari
figur
moreov
retain
strong
inhibitori
potenti
toward
proteolyt
target
show
cyscmpl
cltmpl
fusion
significantli
inhibit
matrigel
invas
neot
cell
effect
former
pronounc
probabl
due
fact
cystatin
c
stronger
inhibitor
cathepsin
b
clitocypin
inhibit
migrat
neot
cell
absenc
matrigel
cyscmpl
fusion
indic
cell
migrat
extracellular
matrix
degrad
reduc
addit
fusion
protein
supplementari
figur
stronger
effect
cyscmpl
fusion
cell
invas
confirm
flow
cytometri
show
signific
decreas
dqcollagen
iv
degrad
cell
treat
cyscmpl
final
point
partial
inhibit
neot
invas
upon
treatment
combin
nonfus
inhibitor
cystatin
c
mpl
indic
incub
lectin
facilit
endocytosi
molecul
present
medium
similarli
shown
fungal
lectin
xcl
stimul
uptak
poorli
intern
molecul
via
clathrindepend
mechan
activ
recombin
fungal
lectin
mpl
carbohydratebind
mutant
express
escherichia
coli
purifi
describ
activ
recombin
cystatin
c
cysc
genbank
access
number
without
signal
peptid
amino
acid
express
e
coli
cysccod
sequenc
amplifi
use
phusion
hot
start
ii
highfidel
dna
polymeras
thermo
scientif
waltham
usa
primer
introduc
ndei
rcyscndeif
bamhi
rcyscbamhirno
fusion
restrict
site
supplementari
tabl
fragment
subclon
appropri
linear
express
vector
novagen
wi
usa
heterolog
express
e
coli
transform
plasmid
cysc
cultiv
lb
medium
supplement
ampicillin
induc
mm
isopropyl
reach
grown
h
bacteri
cell
harvest
centrifug
g
min
plu
sorval
resuspend
mm
trishcl
mm
edta
serva
germani
triton
ph
sonic
min
centrifug
g
min
pellet
suspend
mm
trishcl
mm
edta
urea
ph
dialys
mm
trishcl
ph
recombin
cysc
purifi
use
deaesepharos
anionexchang
column
equilibr
buffer
unbound
fraction
collect
dialys
phosphat
buffer
salin
pb
concentr
ultrafiltr
amicon
recombin
clitocypin
clt
express
e
coli
purifi
describ
two
fusion
peptidas
inhibitor
lectin
connect
spacer
peptid
gggg
construct
cltmpl
cyscmpl
sinc
nterminu
essenti
inhibitori
activ
cystatin
c
ntermin
fusion
mpl
design
proteas
inhibitor
code
sequenc
peptidas
inhibitor
genbank
access
number
rclt
cysc
lectin
rmpl
genbank
access
number
amplifi
phusion
hot
start
ii
highfidel
dna
polymeras
thermo
scientif
correspond
primer
supplementari
tabl
twostep
pcr
incorpor
restrict
site
sequenc
code
part
linker
peptid
result
fragment
code
peptidas
inhibitor
lectin
subclon
express
vector
novagen
yield
fusion
link
peptidas
inhibitor
clt
cysc
lectin
mpl
fusion
heterolog
express
e
coli
transform
construct
express
vector
describ
recombin
cysc
purifi
describ
previous
publish
mpl
mutant
fusion
protein
dimer
form
observ
function
protein
domain
recombin
fusion
cyscmpl
cltmpl
analys
hemagglutin
assay
first
perform
determin
activ
lectin
domain
use
human
blood
group
b
erythrocyt
describ
secondli
inhibitori
activ
cyscmpl
cltmpl
cysc
papain
sigma
mo
usa
determin
constant
inhibit
ki
determin
accord
henderson
linear
equat
tight
bind
competit
inhibitor
papain
activ
nm
final
concentr
follow
addit
differ
concentr
protein
measur
me
buffer
sigma
mm
dtt
fermenta
md
usa
mm
coumarylamid
bachem
switzerland
ph
assay
carri
fluoresc
measur
excitationemiss
wavelength
nm
micropl
reader
infinit
tecan
group
switzerland
viabil
differ
cell
line
follow
addit
protein
sampl
assess
use
mt
assay
celltit
aqueou
one
solut
cell
prolifer
assay
promega
madison
wi
usa
accord
manufactur
instruct
human
cell
line
use
nondifferenti
pma
differenti
histiocyt
lymphoma
cell
atcc
number
malign
nonhodgkin
lymphoma
atcc
number
leukem
cell
jurkat
atcc
number
hepatocellular
carcinoma
cell
atcc
number
neuroblastoma
cell
atcc
number
cervic
cancer
cell
hela
atcc
number
rastransform
human
breast
epitheli
cell
line
neot
deriv
cell
line
atcc
number
mt
cell
viabil
loss
assay
seed
number
viabl
cell
per
well
jurkat
nondifferenti
hela
neot
pma
differenti
cell
maintain
appropri
cultur
media
lectin
ad
cell
plate
viabil
assess
h
h
h
lectin
mpl
mpl
fusion
ad
media
coverslipattach
adher
suspens
cell
line
differ
time
addit
protein
coverslipattach
cell
wash
pb
suspens
cell
wash
pb
centrifug
stat
spin
cytofug
statspin
iri
intern
onto
glass
slide
cell
fix
permeabil
min
incub
paraformaldehyd
electron
microscopi
scienc
pb
follow
min
incub
triton
pb
label
antibodi
aminopeptidas
n
cell
fix
min
ice
cold
methanol
permeabil
min
ice
cold
aceton
nonspecif
stain
block
bsa
pb
h
cell
label
primari
secondari
antibodi
time
hour
bsa
pb
follow
primari
antibodi
use
affinitypurifi
rabbit
antimpl
antibodi
biogen
germani
mous
monoclon
antihuman
antibodi
life
technolog
ca
usa
mous
monoclon
antihuman
antibodi
r
system
mn
usa
mous
monoclon
antihuman
antibodi
r
system
mous
monoclon
antihuman
antibodi
santa
cruz
biotechnolog
usa
secondari
antibodi
use
goat
antirabbit
antibodi
conjug
alexa
fluor
goat
antirabbit
antibodi
conjug
alexa
fluor
donkey
antimous
antibodi
conjug
alexa
fluor
purchas
life
technolog
cell
wash
three
time
pb
perform
step
acid
intracellular
compart
cell
stain
min
incub
nm
lysotrack
red
invitrogen
thermo
scientif
prior
paraformaldehyd
fix
cell
mount
slide
prolong
gold
antifad
reagent
contain
nuclear
dapi
stain
thermo
scientif
membran
label
membraneembed
palmitoyl
green
fluoresc
protein
code
pcaggfp
plasmid
addgen
usa
transfect
cell
done
one
day
advanc
lipofectamin
reagent
life
technolog
follow
manufactur
instruct
inhibit
lectin
bind
andor
intern
achiev
preincub
mpl
min
growth
medium
contain
lactos
final
concentr
sigma
prior
addit
cell
chlorpromazin
final
concentr
sigma
use
inhibit
clathrinmedi
endocytosi
filipin
iii
sigma
inhibit
clathrinindepend
caveolar
endocytosi
millipor
germani
inhibit
retrograd
transport
inhibitor
ad
cell
hour
prior
treatment
protein
immunostain
cell
visual
confoc
microscop
carl
zeiss
germani
equip
uv
nm
argon
nm
nm
hene
nm
nm
laser
imag
acquir
process
use
zen
softwar
carl
zeiss
inhibit
intracellular
peptidas
upon
addit
protein
measur
neot
whole
cell
lysat
cell
tissu
cultur
treat
plate
incub
one
two
hour
presenc
sigma
fusion
mpl
peptidas
inhibitor
clt
cysc
combin
unlink
mpl
peptidas
inhibitor
experi
done
triplic
cell
wash
twice
pb
detach
dissoci
reagent
trypl
select
gibco
thermo
scientif
subsequ
step
carri
cell
centrifug
g
wash
twice
pb
cell
pellet
resuspend
whole
cell
lysi
buffer
mm
hepe
mm
nacl
vv
igep
sigma
ph
incub
minut
lyse
cell
centrifug
g
pellet
discard
protein
concentr
determin
dc
protein
assay
biorad
laboratori
ca
usa
accord
manufactur
instruct
cathepsin
b
l
activ
measur
whole
cell
lysat
lysat
analys
triplic
lysat
incub
black
plate
min
addit
substrat
mm
hepe
mm
edta
mm
dtt
ph
cathepsin
b
ph
cathepsin
l
coumarylamid
substrat
bachem
coumarylamid
substrat
bachem
ad
measur
cathepsin
b
l
activ
respect
kinet
measur
min
excitationemiss
wavelength
nm
micropl
reader
infinit
tecan
data
analys
use
graphpad
prism
softwar
slope
linear
regress
curv
calcul
statist
differ
determin
use
student
ttest
neot
cell
grown
appropri
media
scrape
plate
two
wash
ice
cold
pb
resuspend
fraction
buffer
mm
sucros
mm
hepe
mm
kcl
mm
mm
edta
serva
mm
egta
fluka
germani
mm
dtt
ph
proteas
inhibitor
cocktail
ultra
tablet
roch
switzerland
subsequ
step
carri
cell
pass
needl
time
lyse
dounc
homogenis
pestl
stroke
cell
lysat
incub
min
centrifug
min
g
pellet
wash
fresh
fraction
buffer
pass
needl
time
centrifug
min
g
two
supernat
combin
centrifug
min
g
result
supernat
subject
centrifug
centrikon
ultracentrifug
kontron
instrument
germani
tst
rotor
min
g
pellet
resuspend
pass
needl
time
centrifug
min
g
pellet
dissolv
lysi
buffer
mm
hepe
mm
nacl
vv
igep
sigma
ph
membran
protein
sampl
incub
mpl
lysi
buffer
without
lactos
mpltarget
complex
coimmunoprecipit
magnet
nanoparticl
protein
g
invitrogen
accord
manufactur
instruct
empti
nanoparticl
label
affin
purifi
rabbit
antimpl
biogen
isol
mpl
complex
label
nanoparticl
ad
mixtur
membran
protein
sampl
preincub
lectin
incub
min
tube
rotat
nanoparticl
heat
min
sd
sampl
buffer
mm
dtt
protein
resolv
precast
trisglycin
gel
thermo
scientif
gel
silver
stain
individu
band
excis
follow
ingel
trypsin
digest
identifi
mass
spectroscopi
fingerprint
use
orbitrap
linear
trap
quadrupol
ltq
velo
mass
spectromet
coupl
proxeon
nanolc
hplc
unit
thermo
fisher
scientif
waltham
usa
result
analys
use
scaffold
ms
softwar
proteom
softwar
immunodetect
coimmunoprecipit
mpltarget
complex
resolv
precast
trisglycin
gel
transfer
h
onto
pvdf
membran
membran
block
h
nonfat
dri
milk
trisbuff
salin
tb
primari
antibodi
antihuman
antibodi
r
system
mous
monoclon
antihuman
antibodi
r
system
dilut
block
solut
incub
overnight
antibodyreact
protein
detect
incub
horseradish
peroxidas
hrp
conjug
secondari
anti
mous
antibodi
jackson
immunoresearch
laboratori
inc
block
solut
immunoreact
band
visual
lumilight
plu
westernblot
substrat
roch
imag
acquir
use
geldoc
system
biorad
invas
migrat
neot
cell
assay
real
time
realtim
cell
analys
xcellig
rtca
dp
acea
bioscienc
purpos
cim
plate
prepar
describ
lower
upper
compart
fill
differ
protein
hour
serumstarv
cell
cell
well
ad
upper
compart
degre
cell
invas
migrat
measur
everi
minut
hour
data
acquir
xcellig
rtca
softwar
analys
graphpad
prism
softwar
experi
done
triplic
cell
index
plot
xy
graph
slope
linear
regress
curv
area
curv
calcul
specif
time
interv
statist
differ
determin
use
student
ttest
effect
fusion
protein
combin
protein
intracellular
dqcollagen
iv
degrad
assess
accord
protocol
describ
et
al
neot
cell
plate
well
plate
cell
allow
attach
overnight
media
replac
serum
free
medium
contain
recombin
fusion
combin
protein
h
incub
dqcollagen
iv
invitrogen
ad
cell
incub
addit
h
propidium
iodid
bd
bioscienc
ca
usa
exclus
use
monitor
viabl
cell
measur
perform
bd
fac
calibur
instrument
beckton
dickinson
inc
analysi
use
flowjo
softwar
flowjo
ashland
usa
conclus
fungal
lectin
mpl
shown
toxic
human
cell
line
despit
rapid
intern
sort
golgi
apparatu
lysosom
prolong
retent
observ
recognit
cell
membran
glycoprotein
function
bind
site
subunit
need
properti
mpl
remain
preserv
fuse
protein
design
promis
carrier
protein
drug
intracellular
target
facilit
uptak
molecul
mpl
could
great
valu
variou
biomed
biotechnolog
applic
